30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

Axolotl Biologix Acquired by Private Equity Firm -

Axolotl Biologix, a developer of regenerative medicine products, was acquired by a private equity firm. Terms were not disclosed. The move comes as Axolotl prepares to initiate FDA clinical trials of current and developing biologic products with a range of applications in numerous segments, including orthopedics. Axolotl offers regenerative medicine treatment applications with clinical benefits known to stimulate cellular growth and repair of damaged cells and tissues. Lines with orthopedic application include AxoBioFluid liquid allograft; AxoBioPRP, an autologous kit used to separate platelet-rich plasma from patient’s whole blood; AxoBioBMAC, an autologous kit used to separate bone marrow aspirate concentrated from the patient’s bone marrow draws; and AxoBioADIPOSE, an autologous kit used to separate patient’s adipocytes from adipose tissue. AxoBioFluid is available now, while the remaining products are planned for 2019 launch. (AZ Big Media, 5/8/19)